A Smart + Strong Site
Subscribe to:
E-newsletters
POZ magazine
JOIN AIDSMEDS YouTube

Back to home » Treatment News » Top Stories

Most Popular Stories
An Almost Normal Life Expectancy for People With HIV?
Undetectable Viral Load Essentially Eliminates Transmission Risk in Straight Couples
A 15-Year Jump in Life Expectancy for People With HIV
Misleading News Reports Suggest HIV Cure Is Near
New HIV Drug Class Shows Promise
Gene Therapy Shows Promise in Controlling HIV
Potential Microbicide Tricks HIV Into Sudden Death
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
Aging & HIV
The HIV Life Cycle
Shingles
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to news@aidsmeds.com.

Click here for more news


emailprint

January 6, 2012

New Guidelines: Anti-Seizure Drug Selection for People Living With HIV

New guidelines from the American Academy of Neurology (AAN) and the International League Against Epilepsy (ILAE) have been published online ahead of print by the journal Neurology to help people living with HIV and their care providers choose seizure drugs that do not interact negatively with antiretrovirals (ARVs).

“Drug interactions between AEDs [antiepileptic drugs] and ARVs could result in progression to AIDS and/or reduced seizure control,” said Gretchen Birbeck, MD, MPH, of Michigan State University and a lead author of the recommendations in an accompanying announcement. “Providing guidelines that help physicians select appropriate therapies for their patients with epilepsy and HIV/AIDS will ultimately improve patient outcomes and possibly decrease the public health threat of the development of drug-resistant HIV.”

Seizure disorders, such as epilepsy, are common among people living with HIV, Birbeck and her colleagues note. Up to 55 percent of the 33 million people living with HIV worldwide require treatment with AEDs—used to manage epilepsy, a variety of mood disorders and other neurological complications including peripheral neuropathy—at some point in their lives.

Numerous AEDs are available to these neurological problems, and many can be combined, safely, with ARVs. However, some AEDs are associated with potentially dangerous interactions with available HIV medications.

Because of the way certain AEDs and ARVs are broken down (metabolized) in the body, some seizure medications can significantly increase or decrease blood levels of some HIV drugs, potentially increasing the risk of side effects or HIV drug resistance. Similarly, some ARVs can increase or decrease blood levels of some AEDs, which can also increase the risk of side effects or reduce the effectiveness of anti-seizure therapies.

Unfortunately, the guidelines note, evidence from studies looking at specific drug-drug interactions is weak and, as a result, firm AED selection and dosing recommendations are limited. However, a number of interactions are known and should be considered. Some of the key recommendations in the published guidelines include:

AEDs and Protease Inhibitors

Dylantin (phenytoin) and Kaletra (lopinavir/ritonavir)
People living with HIV receiving phenytoin may require a Kaletra dosage increase of about 50 percent to maintain adequate blood levels of lopinavir, the active protease inhibitor in Kaletra.

Lamactil (lamotrigine) and Norvir (ritonavir)–boosted Reyataz (atazanavir)
People living with HIV receiving Norvir-boosted Reyataz may require a lamotrigine dosage increase of about 50 percent to maintain adequate blood levels of atazanavir.

AEDs and Integrase Inhibitors

Lamactil (lamotrigine) or Versed (midazolam) and Isentress (raltegravir)
Isentress may not require doses of either lamotrigine or midazolam to be adjusted.

AEDs and Nucleoside/Non-Nucleoside Reverse Transcriptase Inhibitors

Depakote (valproic acid) and efavirenz (found in Sustiva and Atripla)
People living with HIV receiving Sustiva or Atripla may not require the dose of valproic acid to be adjusted.

Depakote and zidovudine (found in Retrovir, Combivir and Trizivir)
People living with HIV receiving valproic acid may require a zidovudine dose reduction to maintain normal blood levels of zidovudine.

“Future research should target epilepsy and HIV/AIDS drug combinations where choices are limited, such as in developing countries”—where both AED and ARV drug choices are limited—“to better understand the risks,” Birbeck said. “It also is important that patients know exactly which drugs they are taking and provide that information to all prescribing health care providers caring for them.”

To establish the guidelines, Birbeck and her colleagues systematically reviewed studies published in the medical literature between 1950 and 2010 to determine the prevalence of co-usage of anti-epileptic drugs and antiretrovirals and drug interactions. Nearly 4,500 articles were identified, 68 full studies were reviewed and data from 42 articles were used in the analysis.

Search: epilepsy, seizures, mood disorders, antiepileptic drugs, AED, dylantin, phenytoin, lamactil, lamotrigine, Reyataz, Norvir, versed, midazolam, sustiva, atripla, AZT, zidovudine, depakote, valproic acid, american academy of neurology


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team reviews all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (1 total)


[Go to top]

Quick Links
AIDSmeds en Español
About HIV and AIDS
Lab Tests
Clinical Trials
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Disclosure
Lipodystrophy
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Blogs
Conference Coverage
Health Services Directory
POZ Magazine


    adoniz89
    san dimas
    California


    RyGuy00
    New York
    New York


    max38man
    Chicago
    Illinois


    clintonjrsyr
    syracuse
    New York
Click here to join POZ Personals!
Conference Coverage

21st Conference on Retroviruses and Opportunistic Infections
(CROI 2014)
Boston, MA
March 3 - 7, 2014


7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention
(IAS 2013)
Kuala Lumpur, Malaysia
June 30 - July 3, 2013


20th Conference on Retroviruses and Opportunistic Infections
(CROI 2013)
Atlanta, GA
March 3 - 7, 2013


more conference coverage

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.